Marcadores sorológicos da infecção pelo vírus da hepatite C em trabalhadores e pacientes da Unidade de Diálise do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Góngora, Delzi Vinha Nunes de

doi:10.1590/s0037-86821998000600016

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anti-HCV prevalence observed in this study was lower when compared to other Brazilian studies in Rio de Janeiro (65.0% in 1995), Fortaleza (52.0% in 2004), Goiâ nia (46.7% in 2001), São Paulo (42.5% in 1998), Porto Alegre (29.8% in 1995), Belo Horizonte (20.3% in 2002) [Karohl et al, 1995;Vanderborght et al, 1995;Góngora, 1998;Carneiro et al, 2001;Busek et al, 2002]. Similar seroprevalence rates have been reported in Salvador (10.5% in 2006) and Cuiabá (16.9% in 2007) [Silva et al, 2006;Santos and Souto, 2007].…”

Section: Discussioncontrasting

confidence: 67%

“…International studies with hemodialysis patients have reported anti-HCV seroprevalence rates ranging from 1% to more than 50% in Brazil [Vanderborght et al, 1995;Karohl et al, 1995;Góngora, 1998;Oliveira et al, 1999;Santana et al, 2001;Busek et al, 2002;Souza et al, 2003;Oliveira Penido et al, 2008], Southern Europe [Petrosillo et al, 2001;Djukanović et al, 2002;Fissel et al, 2004], United States [Sivapalasingam et al, 2002], and Japan [Yamaji et al, 1996] with lower rates (1%-10%) in Northern European countries [Allander et al, 1994].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C virus screening and clinical monitoring of biomarkers in patients undergoing hemodialysis

Maia

Martins‐Filho

Teixeira-Carvalho

et al. 2009

Journal of Medical Virology

View full text Add to dashboard Cite

In this study, 395 volunteers were enrolled to investigate the seroprevalence of hepatitis C virus, the immunological and the alanine aminotransferase (ALT) biomarkers amongst hemodialysis patients, living in Manaus, Brazil. An overall seroprevalence of 13.9% was found in the hemodialysis patients. Analysis of seroconversion patterns demonstrated that most patients with HCV seroconverted up to 10 years following the first hemodialysis session. Anti-NS5 antibody was detectable in 60.4% of patients with HCV. A lower percentage of circulating CD3(+) and CD4(+) T-cells was found in patients seronegative for HCV, whereas a higher frequency of CD8(+) T-cells was the hallmark of patients with HCV. An overall low activation state of monocytes and eosinophils were observed in hemodialysis patients. In contrast, a higher frequency of activated neutrophils was observed in patients with HCV, selectively in the NS5+ subgroup. All hemodialysis patients had a higher percentage of activated lymphocytes, with the higher activation state in patients with NS5- reactivity. Higher ALT levels were observed in patients with HCV, especially in the NS5+ subgroup. Interestingly, the ALT levels were correlated negatively with the lymphocyte activation state, selectively in the NS5- subgroup, suggesting a protective role of these activated lymphocytes in patients with HCV. These findings reinforce the importance of the transmission of HCV among hemodialysis patients, suggesting that apart from the HCV screening, the serological and ALT biomarkers may represent important predictors of morbidity and/or mortality among patients undergoing hemodialysis.

show abstract

Section: Discussioncontrasting

confidence: 67%

Section: Introductionmentioning

confidence: 99%

Hepatitis C virus screening and clinical monitoring of biomarkers in patients undergoing hemodialysis

Maia

Martins‐Filho

Teixeira-Carvalho

et al. 2009

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Nevertheless, with reference to other Brazilian hemodialysis populations, anti-HCV prevalence (39%) was higher than those observed previously in Goiânia and Porto Alegre (Karohl et al 1995, Naghettini et al 1997, but similar to that obtained in São Paulo (Góngora 1998), and lower than the prevalence found in Rio de Janeiro . This demonstrates that HCV infection is a significant problem in Brazilian dialysis units.…”

Section: Discussionsupporting

confidence: 50%

“…The prevalence of HCV antibodies (anti-HCV) has been reported to range from 2% in northwestern Europe to 76.3% in Indonesia (Soetjipto et al 1996, Schneeberger et al 1998. In Brazil, surveys have shown that hemodialysis patients have high anti-HCV prevalence rates (29.4%-65%) (Karohl et al 1995, Naghettini et al 1997, Góngora 1998. However, there are strong indications that studies of hemodialysis patients which rely solely on serological screening could underestimate the prevalence of HCV infection considerably (Bukh et al 1993, Caramelo et al 1996.…”

mentioning

confidence: 99%

Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: a survey by polymerase chain reaction and serological methods

Carneiro

Martins

Teles

et al. 2001

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…Prevalence is lower in populations highly selected by previous screening for risk factors associated with the infection, such as blood donors, and is higher among groups highly exposed to parenteral transmission of the virus, such as intravenous drug users or hemodialysis patients 2,13,21,29 . In Brazil, available data usually refer to large centers 8,12,22 .…”

Section: Introductionmentioning

confidence: 99%

Serological, epidemiological and molecular aspects of hepatitis C virus infection in a population from Londrina, PR, Brazil, 2001-2002

Vogler

Nishiya

Morimoto

et al. 2004

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

SUMMARYSerological, epidemiological and molecular aspects of hepatitis C virus (HCV) infection were evaluated in 183 subjects from Londrina, Paraná, Brazil, and adjacent areas. Serum samples which tested anti-HCV positive by microparticle enzyme immunoassay (MEIA) obtained from eight patients with chronic hepatitis C, 48 blood donors, and 127 patients infected with the human immunodeficiency virus (HIV) were submitted to another enzyme immunoassay (ELISA) and to the polymerase chain reaction (PCR). About 78.7% of samples were also reactive by ELISA, with the greater proportion (70.8%) of discordant results verified among blood donors. A similar finding was observed for HCV-RNA detection by PCR, with 111/165 (67.3%) positive samples, with higher rates among HIV-positive subjects and patients with chronic hepatitis than among blood donors. Sixty-one PCRpositive samples were submitted to HCV genotyping, with 77.1, 21.3 and 1.6% of the samples identified as types 1, 3 and 2, respectively. Finally, analysis of some risk factors associated with HCV infection showed that intravenous drug use was the most common risk factor among HIV/HCV co-infected patients, while blood transfusion was the most important risk factor in the group without HIV infection. The present study contributed to the knowledge regarding risk factors associated with HCV infection and the distribution of HCV genotypes in the population evaluated. KEYWORDS:Hepatitis C virus; Anti-HCV; Genotypes; Epidemiology. INTRODUCTIONAbout 170 million people all over the world are infected with hepatitis C virus (HCV), although many ignore such fact 30 . In most cases, the infection develops as an asymptomatic clinical picture but with severe consequences, since about 80% of the infected subjects develop chronic hepatitis, cirrhosis or hepatocellular carcinoma 16,28 .Co-infection of HCV-infected subjects with the human immunodeficiency virus (HIV) has important implications for the prognosis and management of both diseases. These subjects show elevated alanine aminotransferase levels and are at a higher risk of developing fibrosis, cirrhosis, liver failure or hepatocellular carcinoma than subjects infected only with HCV 6 ; in addition, they show a higher risk of developing hepatic toxicity related to the use of highly active antiretroviral therapy than patients infected only with HIV 5,26 .The use of the polymerase chain reaction (PCR) for the detection of HCV-RNA allows the identification of the presence of active HCV infection. However, RNA levels may show fluctuations with nondetectable periods even in patients not submitted to interferon therapy 7 .Patient counseling regarding the risk-benefit of treatment also requires analysis of a liver biopsy and the determination of the HCV genotype. Differences in the response to treatment depending on the HCV genotype have been observed, with type 1 being more resistant than types 2 and 3 19 . Genotyping based on the amplification of the 5' untranslated region (5'-UTR) has the advantage that it can be performed on PCR ...

show abstract

Marcadores sorológicos da infecção pelo vírus da hepatite C em trabalhadores e pacientes da Unidade de Diálise do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Cited by 7 publications

References 0 publications

Hepatitis C virus screening and clinical monitoring of biomarkers in patients undergoing hemodialysis

Hepatitis C virus screening and clinical monitoring of biomarkers in patients undergoing hemodialysis

Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: a survey by polymerase chain reaction and serological methods

Serological, epidemiological and molecular aspects of hepatitis C virus infection in a population from Londrina, PR, Brazil, 2001-2002

Contact Info

Product

Resources

About